Explore the latest news from Khondrion and its team.
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program to progress clinical development...
Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission...
Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the...
KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.
How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...
2020 – A Year in Review As a new year approaches, Khondrion’s CEO Jan Smeitink reflects on 2020 and the progress Khondrion has made in its research...
1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the...
Estimated to affect more than 400 million people around the world, diabetes is one of the most common chronic disorders, with a range of different...
Mitochondrial diseases are a clinically, biochemically and genetically heterogeneous group of disorders. Signs, symptoms and the organs involved can...
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
